Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Mind Cure Health Inc (OP: MCURF )

N/A UNCHANGED
Last Price Updated: 2:36 PM EDT, Sep 11, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Mind Cure Health Inc

Cannabis Movers & Shakers: TrueGreen, PSYC, BioSteel Sports Nutrition, Perfect Union, YourWay Cannabis Brands
Via Benzinga
Are Psychedelics Stocks In Trouble Or Is The Market Reaching Maturity?
Long gone is the heyday of investor enthusiasm and easy access to capital that marked the launch of the psychedelics industry into the public markets. In recent months, psychedelics stocks entered into... 
Via Benzinga
Psyched: MindCure Shuts Down Operations, Novamind And MindMed Partner For Study
The psychedelics space was shaken up on the news thatMindCure Health (OTC: MCURF) was shutting down operations. 
Via Benzinga
Mind Cure Health Is Shutting Down All Operations, Citing Lack Of Funds To Move Forward
Mind Cure Health Inc. (CSE:MCUR) (OTCQX: 
Via Benzinga
Benzinga Expands Footprint into the Psychedelic Industry with the Launch of the Benzinga Psychedelic Advisory Council
DETROIT, March 4, 2022 /PRNewswire/ -- The Benzinga Psychedelics Advisory Council is a collective of the leading minds and voices in the ... 
Via Benzinga
Psychedelics As A Potential Form Of Treatment For Traumatic Brain Injuries
In recent years, there has been a re-emergence in the study of psychedelic drug... 
Via Benzinga
Epigenetics, Psychedelics and Stem Cell Therapy are Topics of the Life Sciences Virtual Investor Conference Launching This Thursday
Photo by Chris Montgomery on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
This Company Is Making Synthetic Psychedelics With a Goal To Combat Mental Illness
Photo by Michael Longmire on... 
Via Benzinga
EXCLUSIVE: Benzinga Interviews Mind Cure CEO Kelsey Ramsden with Updates on Latest Press Release
Image by: iStock The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored conte... 
Via Benzinga
Compass Pathways 2.0: A New Rally In Psychedelic Stocks?
Compass Pathways' IPO sparked a sector-wide rally in 2020. Now CMPS is on the move again. Is history about to repeat? 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Psyched: MindMed's MDMA Program For Autism, Small Pharma's New Patent, NovaMentis' Orphan Drug Designation
The Week In Psychedelics: 
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
The Week In Psychedelics 
Via Benzinga
Psychedelic Stocks: Financial Strength, Growth Potential, Compelling Valuations
Blue-chip stocks: grossly inflated valuations and loaded with debt. Psychedelic stocks: lean valuations and loaded with cash. A very attractive option in uncertain markets. 
Via Talk Markets
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
Just two years ago, the psychedelics sector was a small research space reserved for academics and extremely forward-thinking investors. S... 
Via Benzinga
Psyched: Elon Musk Discusses Psychedelics, Delix Raises $70M, MindCure To Study MDMA In Female Sexual Dysfunction
The Week In Psychedelics: 
Via Benzinga
Can MDMA (Or Ecstasy) Improve Sexual Desire in Women? MindCure Launches Research Program To Find Out
Mind Cure Health Inc. (CSE:MCUR) (OTCQB: 
Via Benzinga
Is Ketamine A Psychedelic? Depends On Who You Ask
Ketamine, an FDA-approved anesthetic drug, has recently become the star of the psychedelic medicine movement. As p... 
Via Benzinga
Psychedelic Medicine's Top CEOs: Who's Running The Biggest Companies In This Booming Industry?
By Natan Ponieman and Javier Hasse The psychedelic medicine industry is growing by leaps and bounds. Leading this charge is a group of ambitious and visionary corporate... 
Via Benzinga
Psychedelic Drug Industry Report Card For 2021
In assessing the psychedelic drug industry, a primary focus for investors is drug development. 
Via Talk Markets
Psyched: Cybin Gets $9 Price Target, FSD Pharma Acquires Lucid, New Trials From Psilera, Awakn, PharmaDrug And Braxia, California Bill Put On Hold
Contents 
Via Benzinga
Which Psychedelic Drug Has The Most Commercial Potential?
As the Mental Health Crisis has become a mental health pandemic, clinical research on psychedelic drugs is showing that these substances are the best – and only – option to address this crisis. 
Via Talk Markets
How To Invest In "Magic Mushrooms" (Psychedelics)
A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. 
Via Talk Markets
Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies
Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... 
Via Benzinga
Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More
Institutional analysts are taking a liking to the industry ... 
Via Benzinga
Professional Sports Turn To Psychedelics
Psychedelic drug R&D is rapidly expanding into many of the largest medical treatment markets. 
Via Talk Markets
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
Concentration of ownership in psychedelic drug stocks has reached a new extreme. We explain how and why we don't see this trend as being sustainable. 
Via Talk Markets
The Next Psychedelic Stock To Uplist On The Nasdaq?
As MindMed Inc makes its long-awaited move to the Nasdaq, the obvious question is: who's next? 
Via Talk Markets
Second-Chance Buying Opportunity With Psychedelic Stock Warrants
Psychedelic stock warrants delivered epic returns for investors in the big rally in these stocks in 2020. After the pullback in 2021, some of these warrants are again looking attractive. 
Via Talk Markets
Déjà Vu: 2021 Slump In Psychedelic Stocks Mirrors 2020
Charts for most psychedelic drug stocks look terrible in recent weeks. The same was true in the summer of 2020 -- immediately before these stocks exploded higher. Deja vu? 
Via Talk Markets
Cannabis Movers & Shakers: TILT, BRNT, ECGI, Alcanna, WeedMD, Mind Cure, Flowr Corporation, VIVO, Cannabiz, Team Hytiva
TILT Holdings Announces Two New Additions To Its Leadership Team TILT Holdings Inc. (CSE: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.